A child plays EndeavorRx, Akili's prescription video game for ADHD.Akili Interactive The digital-therapeutics pioneer Pear was sold for parts in an auction on May 18 for $6 million. Companies like Pear and Akili have struggled to get payers and providers on board with their tech. Experts warn more that failures may be on the horizon for the $3.9 billion industry. A group of healthcare companies has spent the past decade building new technologies to treat patients with prescription software, creating an industry worth $3.9 billion and growing fast.But the industry's pioneers have stumbled, raising questions about the future of the nascent market — including which companies will make it to the other side.In 2017, Pear Therapeutics became the first company to receive clearance from the Food and Drug Administration for a prescription digital therapeutic, with its app to treat substance-use disorders.